secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lineage Cell Therapeutics, Inc. (LCTX)
CIK:        0000876343
Form:       8-K
Filed at:   2022-08-11T23:59:59+00:00
Accession:  0001493152-22-022077
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lineage reports Q2 net loss of $6.8M ($0.04/sh); cash $72M supports through Q2 2024
--------------------------------------------------------------------------------

- Revenue $4.6M, up $4.0M YoY, primarily from Roche collaboration licensing fee.
- Net loss attributable to Lineage $6.8M ($0.04/sh) vs $4.8M ($0.03/sh) in Q2 2021.
- R&D expenses $3.3M; G&A $5.3M; total operating expenses $8.6M.
- Cash, equivalents, and marketable securities $72M; funds operations through Q2 2024.
- OpRegen collaboration with Roche advancing; OPC1 results published in J Neurosurg; VAC2 tech transfer complete.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/876343/000149315222022077/0001493152-22-022077-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/876343/000149315222022077/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-022077

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer